Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonsetamig for Desensitization in Highly HLA-Sensitized Chronic Kidney Disease Patients Awaiting Kidney Transplantation
NCT05092347Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vonsetamig in chronic kidney disease (CKD), sponsored by Regeneron Pharmaceuticals. Started Aug 2022; status: active, not recruiting.
02
Drugs
vonsetamig
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05092347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092347.